Expand BIOA Menu
BIOA MENU

BIOA Latest Press Releases

-- January 21, 2026 --

BioAge Announces Pricing of Upsized $115.0 Million Public Offering Globe Newswire 10:30 PM

-- January 20, 2026 --

BioAge Announces Proposed Public Offering Globe Newswire 4:01 PM
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 Globe Newswire 9:00 AM

-- January 12, 2026 --

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk Globe Newswire 9:00 AM

-- December 4, 2025 --

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor Globe Newswire 9:00 AM

-- November 25, 2025 --

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference Globe Newswire 4:30 PM

-- November 7, 2025 --

BioAge Labs to Present at Jefferies Global Healthcare Conference in London Globe Newswire 9:00 AM

-- November 6, 2025 --

BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates Globe Newswire 4:45 PM

-- October 2, 2025 --

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 7:27 AM

-- September 15, 2025 --

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor PRNewswire 9:30 AM
Market Data Delayed 15 Minutes